Physician profile
William D Ryan
NPI 1104924570
$818.26
in general payments reported to CMS, 2019-2025
13 companies · $24.91 in 2025
The $24.91 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $73.29 · 2022: $114 · 2023: $119 · 2024: $210 · 2025: $24.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $354.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $190.93 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Pfizer INC. | $162.41 | 2019-2024 | |
| Procept Biorobotics Corporation | $119.04 | 2023 | Aquabeam Robotic System |
| Medtronic, INC. | $100.00 | 2022 | |
| Stryker Corporation | $52.03 | 2024 | T2 Alpha, Pro, Variax |
| Daiichi Sankyo INC. | $44.90 | 2024 | Injectafer |
| Novo Nordisk INC | $29.19 | 2020-2024 | Rybelsus, Ozempic |
| Sumitomo Pharma America, INC. | $26.22 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $26.10 | 2019 | |
| Edwards Lifesciences Corporation | $24.91 | 2025 | |
| Dexcom, INC. | $14.98 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $14.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.